VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | First analysis of VenDd +/- V for RRMM shows unprecedented reponse

Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, discusses the first analysis from M15-654 (NCT03314181), a phase I/II, non-randomized, multicenter study of venetoclax in combination with daratumumab and dexamethasone (VenDd), with or without bortezomib (V), in patients with relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter